ADA2 and Hypoglycemia: We can hypothesize that gene dosage alterations of GAB4 and ADA2 and their possible functional interactions could be subject of changes in carbohydrate metabolism and these are likely the cause of hypoglycaemia susceptibility of the presented patient.